A registry for documenting integrative oncology treatments in relation to the quality of life of patients with cancer
- Gender
- Women and men
- Age
- 18 years and older
- Trial type
- Observational
- Line of therapy
- all
- Phase
- —
What is this trial about?
Integrative oncology involves the concurrent use of measures such as lifestyle changes (diet, exercise, sleep, and stress management), mind-body interventions (e.g., meditation, yoga, Tai Chi, acupuncture, or massage), and complementary treatments in addition to standard cancer therapy. The goal of the PRIO Registry is to document which complementary measures patients use as part of integrative oncology and whether these are associated with a better quality of life and higher satisfaction. Eligible participants include women and men aged 18 and older with cancer who are being treated at Ulm University Hospital. The study is not limited to specific types of tumors.
Detailed description
Depending on the type and stage of cancer, treatment typically involves surgery, chemotherapy, radiation therapy, or newer targeted drugs. Integrative oncology is a holistic approach that complements—but does not replace—standard-of-care cancer treatment. It encompasses scientifically validated practices such as nutrition, exercise, stress management, and sleep hygiene, as well as so-called mind-body techniques (e.g., meditation, yoga, tai chi) and, in some cases, complementary supplements. The goal is to alleviate symptoms, increase resilience, promote well-being, and strengthen patients’ self-efficacy. Many people are interested in these additional options; however, there is currently a lack of systematic scientific data on their use, effectiveness, and impact on quality of life as well as physical and mental health.
The registry is therefore designed to systematically document the use of integrative oncology interventions and their relationship to quality of life and symptoms. During the initial visit, patients will complete questionnaires on demographics, lifestyle, interventions used, symptom burden, quality of life, fatigue, sleep, mental health, and satisfaction. These assessments will be repeated after 3, 6, and 12 months and subsequently on an annual basis. Additional surveys are planned in the event of specific occurrences, such as a relapse. The study is non-interventional; that is, standard therapy is not altered, and no new medications or treatments are being tested. The registry is also intended to serve as a foundation for future studies.
Facts
- Which disease: all cancers (malignant neoplasms)
- Cancer characteristics: participation of all patients at the Comprehensive Cancer Center Ulm (CCCU); no restriction to specific tumor types
- What the study examines: systematic documentation of the use of integrative oncology measures and their association with quality of life and symptoms
- Study objective: to gain a better understanding of which measures are used and how they relate to quality of life, symptoms, and satisfaction
- How long does the study last: Baseline assessment + follow-up visits at 3, 6, and 12 months, as well as annually; the study is ongoing
- Study characteristics: Prospective, non-interventional registry study; no testing of new medications or therapies
Trial sites
1 trial site in Germany is listed.
Universitätsklinikum Ulm
Ulm
Status unknown
This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.
- Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
- PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine
This description was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.


